Revisiting the thrifty substrate hypothesis: Ketone bodies as cardioprotective fuels in diabetes and SGLT2 inhibitor therapy

Revisiting the thrifty substrate hypothesis: Ketone bodies as cardioprotective fuels in diabetes and SGLT2 inhibitor therapy

Saved in:

Bibliographic Details
Main Authors:	Yoriyasu Suzuki, Tetsuya Amano
Format:	Article
Language:	English
Published:	Wiley 2025-07-01
Series:	Journal of Diabetes Investigation
Online Access:	https://doi.org/10.1111/jdi.70068
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Double Duty: SGLT2 Inhibitors as Cardioprotective and Anticancer Allies
by: Linda Piras, et al.
Published: (2024-11-01)

Trade-offs in relative limb length among Peruvian children: extending the thrifty phenotype hypothesis to limb proportions.
by: Emma Pomeroy, et al.
Published: (2012-01-01)

Cardioprotective Effect of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients: A Multicenter Propensity Score Matched Study
by: Jeong-Hoon Lim, et al.
Published: (2024-08-01)

The Carbon Footprint of the Thrifty Food Plan Can Be Reduced Without Increasing Cost or Reducing Nutritional Quality
by: Derek Jin, et al.
Published: (2025-05-01)

Ketone Bodies Mediate Antiseizure Effects
by: Jena M. Krueger, et al.
Published: (2015-10-01)

Mechanism of substrate recognition and release of human SGLT2
by: Wenhao Cui, et al.
Published: (2025-08-01)

The effects of the ketone body ?-hydroxybutyrate on the neuronal transcriptome
by: Zayn Cheema, et al.
Published: (2025-02-01)

Dipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection
by: Elena Nikolaevna Trunina, et al.
Published: (2011-06-01)

Factors influencing the selection of an SGLT2i vs. a GLP-1RA as cardioprotective agent in patients with type 2 diabetes
by: Shubham Agarwal, et al.
Published: (2025-05-01)

Ketone Body Induction: Insights into Metabolic Disease Management
by: Byung Min Yoo, et al.
Published: (2025-06-01)

Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor
by: Mohamed Alhemeiri, et al.
Published: (2022-01-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
by: A. M. Mkrtumyan, et al.
Published: (2021-09-01)

α-Heteroarylthiomethyl ketones: Small molecule inhibitors of 3CLpro
by: Knez Damijan, et al.
Published: (2025-06-01)

Single cell transcriptomic analysis of SGLT2 expression supports an indirect or off-target role for the cardioprotective benefits of empagliflozin in heart failure
by: Omar Mourad, et al.
Published: (2025-03-01)

Ketone body oxidation increases cardiac endothelial cell proliferation
by: Eva‐Maria Weis, et al.
Published: (2022-02-01)

Characteristics of Cardiac Ketone Body Metabolism Throughout the Life Cycle
by: Lei Li, et al.
Published: (2025-01-01)

The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients
by: Jia-Yuh Sheu, et al.
Published: (2024-11-01)

Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors
by: Selin Genc, et al.
Published: (2024-11-01)

Role of SGLT2 inhibitors in the treatment of visceral obesity
by: M. A. Druzhilov, et al.
Published: (2021-02-01)

Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
by: Dana Darwish, et al.
Published: (2025-06-01)

Osteomyelitis Pubis After Initiation of an SGLT2 Inhibitor
by: Adriana Nadeau, et al.
Published: (2022-10-01)

The impacts of SGLT2 inhibitors on the mortality of patients with tuberculosis
by: Chung-Shu Lee, et al.
Published: (2025-05-01)

Advances in the mechanism of action of SGLT2 inhibitors on the kidney
by: JI Ying, et al.
Published: (2020-01-01)

A study on the pharmacovigilance of various SGLT-2 inhibitors
by: Yanwen Dong, et al.
Published: (2025-01-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

CARDIOPROTECTIVE AND NEPHROPROTECTIVE EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR RAMIPRIL
by: D. A. Napalkov, et al.
Published: (2016-01-01)

The Effect of Frailty on Body Composition and Its Impact on the Use of SGLT-2 Inhibitors and GLP-1RA in Older Persons with Diabetes
by: Alan Sinclair, et al.
Published: (2025-06-01)

SGLT2 inhibitor use and renal outcomes in low-risk population with diabetes mellitus and normal or low body mass index
by: Hye Ryoun Jang, et al.
Published: (2025-04-01)

Revisiting Balassa-Samuelson Hypothesis for Asia – A Critical Appraisal of Literature
by: Maryam Ishaq, et al.
Published: (2023-01-01)

A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD
by: Jheng-Yan Wu, et al.
Published: (2025-08-01)

The Value of Ketone Bodies in the Evaluation of Kidney Function in Patients with Type 2 Diabetes Mellitus
by: Yimei Li, et al.
Published: (2021-01-01)

Ketone body, as an emerging modulator of metabolic reprogramming and epigenetics in breast cancer
by: Fatemeh Mehdikhani, et al.
Published: (2025-09-01)

Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety
by: Bing Zhang, et al.
Published: (2025-07-01)

The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation.
by: Yongin Cho, et al.
Published: (2025-01-01)

SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
by: Vladimir V Salukhov, et al.
Published: (2021-01-01)

A Review on the Relationship between SGLT2 Inhibitors and Cancer
by: Hao-Wen Lin, et al.
Published: (2014-01-01)

Hepatoprotective Benefits of SGLT-2 Inhibitors and GLP-1 Analogs
by: Divya Rajagopal, et al.
Published: (2024-10-01)

New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia
by: Cheng-Hsien Hung, et al.
Published: (2024-12-01)

Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors
by: Filip Rolski, et al.
Published: (2025-02-01)